Perlan Therapeutics Inc. announced Thursday the appointment of Sterling C. Johnson, to the positions of president and member of the board of directors.
Johnson will lead Perlan’s licensing, partnering, merger and acquisition, and strategic planning activities. He joins Perlan from Biota Holdings of Melbourne, Australia, where he served as vice president of global business development.
“Sterling’s extensive industry experience in business development, licensing, and corporate strategic planning puts us in a strong position to maximize the value of our optimization technology as well as our portfolio of drugs currently in development,” said Robert Jaffe, chairman of the board and president of Sorrento Ventures. “The addition of Sterling adds important breadth to our management team and reinforces our commitment to building strategic growth opportunities.”
Johnson's business career has included a range of sales, marketing and senior management assignments throughout the world. His management experience includes: president and CEO of Escalon Ophthalmics; president and CEO of Escalon Medical; president and CEO of Biota, Inc. Johnson’s expertise is in the establishment of new enterprises, business development and licensing, according to a Perlan statement. This includes negotiation and execution of more than 80 joint venture, merger, acquisition and license agreements in the U.S., Europe and Japan in the fields of medical devices, human pharmaceuticals, drug delivery, animal health and agri-chemicals.
Perlan Therapeutics Inc. is an innovative developer of protein-based pharmaceuticals. The company’s proprietary technology platform is the basis for the development of high potency, cost-effective, protein-based therapeutics and diagnostic products. Executive, Position(s)
Sterling C. Johnson: President
Michele Yelmene: Exec. Dir. of Clinical and Regulatory Affairs